Intelligent Bio Solutions Inc 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Intelligent Bio Solutions Inc 's ROA in the fourth quarter of 2026?
Intelligent Bio Solutions Inc recorded a cumulative net loss of $-12 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -110.6%.

However, within the Healthcare sector 757 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4306, from total ROA ranking in the third quarter of 2026 at 5029.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	44.75 %	55.07 %	-40.13 %	-14.39 %	-40.13 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-12	-12	-11	-11	-11
Return On Assets (TTM)	-110.6 %	-112.6 %	-125.52 %	-104.73 %	-97.88 %
INBS's Total Ranking	# 4306	# 5029	# 4400	# 4446	# 4445
Total Assets (TTM) in million	12	15	8	10	8
Seq. Total Assets Change	-19.65 %	80.16 %	-17.82 %	21.68 %	-13.93 %
Seq. Net Income Change	-	-	-	-	-

INBS's 5 Years Annual ROA >> Back to INBS Management Effectiveness >> Compare INBS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 179
Sector	# 758
Overall	# 4256

Return On Assets Statistics
High	Average	Low
-37.87 %	-84.61 %	-134.06 %
(Sep 30 2021)		(Dec 31 2023)

News about Intelligent Bio Solutions Inc Return on Assets ROA

Bio Solutions Advances with Successful In-Clinic Testing and Plans for FDA Submission Amid Financial Challenges

Factual Intelligent Bio Solutions Inc. (INBS), a company focused on developing innovative healthcare solutions, has recently made significant strides in its regulatory journey. The company successfully concluded in-clinic testing associated with its proposed clinical study plan directed to the U.S. Food and Drug Administration (FDA) earlier this year. This achievement marks an important step toward the company’s FDA 510(k) submission, critical for bringing its medical device to market. Details of In-Clinic Testing The in-clinic testing was designed in accordance with the clinical study plan that INBS submitted to the FDA. Completing this testing is a vital component of the regulatory pathway, as it provides empirical data that supports the safety and efficacy of the product under investigation. The outcomes of this testing phase are essential not only for compliance with regulatory standards but also for instilling confidence in potential stakeholders and investors regarding the company s product viability.

Greenhouse Giant Thanet Earth Boosts Safety with Bio Solutions Fingerprint Drug Test Amid Financial Strides,

Enhancing Workplace Safety: Thanet Earth Adopts Intelligent Bio Solutions Fingerprint Drug TestIn a strategic move aimed at improving workplace safety, Thanet Earth, the UK s largest greenhouse complex, has adopted Intelligent Bio Solutions Inc. s (Nasdaq: INBS) Intelligent Fingerprinting Drug Screening System. This adoption reflects the growing need for robust drug testing methods in various industries, as companies strive to ensure a safe and productive work environment. A New Era for Workplace SafetyThanet Earth, renowned for producing approximately 400 million tomatoes, 30 million cucumbers, and 24 million peppers annually, has taken a proactive step in ensuring the safety and well-being of its workforce. By integrating the Intelligent Fingerprinting Drug Screening System, the greenhouse complex aims to maintain high safety standards while minimizing the potential risks associated with drug use in the workplace. Intelligent Bio Solutions drug screening system offers a rapid, non-invasive testing solution, which is crucial for a sizable workforce. Unlike traditional drug testing methods, this system uses fingerprint sweat analysis, delivering quick and reliable results. This advancement aligns with contemporary needs for efficiency and accuracy in occupational health and safety protocols.

Financial Statements
Intelligent Bio Solutions Inc 's Assets	$ 12 million	INBS's Balance sheet
Intelligent Bio Solutions Inc 's Income	$ -4 million	Quarterly INBS's Income Statement
INBS's Income by Division		See INBS's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	44.75 %	-40.13 %	33.07 %	-16.17 %	85.72 %
Total Assets in million	12	8	14	10	12
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-12	-11	-10	-11	-8
Annual Return On Assets	-104.41 %	-128.55 %	-73.96 %	-102.99 %	-67.47 %

INBS's 5 Years Annual ROA >> Back to INBS Management Effectiveness >> Compare INBS ROA to its Competitors

More Return On Assets Ratios
INBS's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INBS's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INBS's Competitors
Subscribers only: Roa for Intelligent Bio Solutions Inc 's Suppliers
Subscribers only: Return On Assets for INBS's Customers

You may also want to know
INBS's Roi	INBS's Inventory Turnover Ratio	INBS's Growth Rates	INBS's Dividend Comparisons
	INBS's Profitability Ratios	INBS's Asset Turnover Ratio	INBS's Dividend Growth
INBS's Roe	INBS's Valuation Ratios	INBS's Financial Strength Ratios	INBS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-29T05:33:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.